Navigation Links
COR in Medical News

Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results

... costs. "The recent completion of the cor Phase 3 program was a major milestone for ... co-primary endpoints. Key top-line data from the cor Phase 3 program include the following: ... Key secondary endpoints met in the cor Phase 3 program included significant improvements ...

Cantel Medical's Mar Cor Purification Subsidiary Acquires G.E.M. Water Systems ... Establishing a Nationwide Reach in Water Treatment

... MEDICAL CORP. (NYSE: CMN ), through its Mar cor Purification subsidiary, has continued the ... year. Curt Weitnauer, President of Mar cor Purification, stated, "Adding G.E.M.'s strong ... foundation for a West Coast expansion of the Mar cor service business." Cantel's President and ...

-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments-

... half of 2010. Key top-line data from the cor Phase 3 program include the following: ... Key secondary endpoints met across the entire cor Phase 3 program included significant improvements ... generally well tolerated by patients across the cor Phase 3 program. ...

Rcadia Medical Imaging Closes $3.3 Million Investment Led by BioVentures Investors

... -- Rcadia Medical Imaging, Ltd., developer of the cor Analyzer(TM) software for the automated analysis ... after a Coronary CTA study, the cor Analayzer(TM) identifies patients who need ... will fund the full commercial launch of the cor Analyzer(TM) and the establishment of a U.S. ...

Landmark Study Aims to Improve Osteoporosis Care Standards Worldwide

... as the population ages. About the Center for Outcomes Research (COR) cor is based at the University of Massachusetts, Worcester, MA, USA. The mission of cor is to collect and evaluate data that reflect real world practices and ...

Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer

... Mr. Kailian was the Chief Executive Officer, President, and a director of cor Therapeutics, Inc. He became the CEO of cor shortly after the company was founded, took the company public in 1991, ...

NUCYNTA(TM) (tapentadol) CII Immediate Release Tablets Now Available for Relief of Moderate to Severe Acute Pain

... with conditions accompanied by hypoxia, hypercapnia or decreased respiratory reserve such as: asthma, chronic obstructive pulmonary disease or cor pulmonale, severe obesity, sleep apnea syndrome, myxedema, kyphoscoliosis, CNS depression, or coma. In such patients, even usual therapeutic doses ...

Xanodyne Announces Appointment of Mr. Vaughn M. Kailian of MPM Capital to the Board of Directors

... and the New England Healthcare Institute. Mr. Kailian has numerous accomplishments in the pharmaceutical industry including serving as CEO of cor Therapeutics, Inc. (1990-2002) where he took the company public in 1991, raised almost $1 billion in public market capital, and led the $2 billion ...

Conrad A. Conrad Elected Chairman of the Board for Rural/Metro Corporation

... joined the Rural/Metro Board of Directors in October 2005 and has served as a member of both the Audit and Compensation committees. He succeeds Mr. cor Clement, who announced earlier this year he would retire from the Board of Directors at the end of June. "I am honored to serve as Chairman of the ...
COR in Medical Technology

Rcadia's COR Analyzer Family of Products Receives Second FDA Clearance

... Drug Administration (FDA) clearance to market its cor Analyzer family of products, which assists in ... a high negative predictive value (NPV). Rcadia's cor Analyzer system uses proprietary image ... who do not have coronary artery disease. "The cor Analyzer is expected to assist the ED staff in ...

New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal

... with conditions accompanied by hypoxia, hypercapnia or decreased respiratory reserve such as: asthma, chronic obstructive pulmonary disease or cor pulmonale, severe obesity, sleep apnea syndrome, myxedema, kyphoscoliosis, CNS depression, or coma. In such patients, even usual therapeutic doses ...

FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain

... with conditions accompanied by hypoxia, hypercapnia or decreased respiratory reserve such as: asthma, chronic obstructive pulmonary disease or cor pulmonale, severe obesity, sleep apnea syndrome, myxedema, kyphoscoliosis, CNS depression, or coma. Patients receiving other mu-opioid agonist ...

International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis

... by prolonged bed rest, age over 60, or a previous history of VTE. About cor (Center for Outcomes Research) The Center for Outcomes Research (COR) ... data management and publication development. Established in 1994, cor is an outgrowth of the Worcester Deep Vein Thrombosis Study, a five-year ...
COR in Medical Definition

Pathology

... Angina pectoris - Prinzmetal's angina - Myocardial infarction - Dressler's syndrome Pulmonary circulation Pulmonary embolism - cor pulmonale Pericardium Pericarditis - Cardiac tamponade Endocardium / heart valves Endocarditis - Mitral regurgitation - ...
COR in Medical Dictionary

Cor pulmonale

... cor pulmonale is failure of the right side of the ... Continued Below Right -sided heart failure - cor pulmonale ... cor PULMONALE - Enlargement of the right ...

Congenital Heart Disease

... babies (8 per 1,000). This figure is an underestimate since it does not include some common problems, namely: ... congenital heart disease cor pulmonale pulmonary fibrosis Polycythemia vera Dehydration (such as from severe diarrhea ) Renal ( kidney ) disease with high ...
COR in Biological Technology

Global Study Shows That Majority of Women with Osteoporosis Do Not Consider Themselves at Higher Risk for Fractures

... About the Center for Outcomes Research (COR) cor is based at the University of Massachusetts, Worcester, MA, USA. The mission of cor is to collect and evaluate data that reflect real world practices and ...

The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis

... acute medical or surgical patients were eligible for the survey. About cor (Center for Outcomes Research) The Center for Outcomes Research (COR) ... data management and publication development. Established in 1994, cor is an outgrowth of the Worcester Deep Vein Thrombosis Study, a five-year ...

Follica Appoints Drug Development and Dermatology Veteran, William D. Ju, as Chief Executive Officer

... technology. The firm's investments in life sciences include: ArthroCare, Aspreva Pharmaceuticals Corporation (acquired by Galenica group, SWX: GALN), cor Therapeutics (acquired by Millennium Pharmaceuticals), Corixa (acquired by GlaxoSmithKline, GSK), Coulter Pharmaceutical (acquired by Corixa ...

Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US

... relationships for each measured company, using TNS Healthcare's proprietary TRI*M(TM) Index. R ela t ionship S cor e s Fall e ven f or T o p C o mpanies Even for companies earning high ratings ...

Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors

... the appointment of Roger G. Stoll, Ph.D. to Delcath's Board of Directors. Dr. Stoll is Executive Chairman of Cortex Pharmaceuticals, Inc. (Amex: cor ), a biotechnology company specializing in the treatment of central nervous system disorders. (Logo: ...

MAP Pharmaceuticals Appoints Marco Rosa Vice President of Human Resources

... launch of several ophthalmology and surgical microscopy devices. Prior to Carl Zeiss, Mr. Rosa served as Vice President, Human Resources at cor Therapeutics, Inc., building the development and commercial organizations and launching Integrilin(R) in the cardiovascular angioplasty market. ...

Xenome Names Ian T. Nisbet, PhD as Chief Executive Officer

... at Millennium he was project leader for the US approval and launch of VELCADE(R) and was part of the team that managed the merger of Millennium and cor Therapeutics in 2001. During his period as CEO of Meditech, Ian led the negotiations with Alchemia that resulted in the first merger of two ...
Other Contents
(Date:7/12/2014)... Using and carrying around a catheter ... from Ashland, Va., decided that there needed to be ... to conceive of our design," he said. , They ... which provides an inconspicuous way to use and carry ... as promotes comfort and peace of mind. Producible in ...
(Date:7/12/2014)... July 12, 2014 “Critical Care ... New and Late-Stage Four-Factor PCCs and Recombinant Products ... the critical care market in the US, UK, ... report provides an estimation of market size for ... covers critical care indications that are being treated ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 A recent article ... provides a trio of suggestions for those seeking cosmetic ... days are rapidly approaching and the heat begins to enliven ... to their summer clothing, realizing that they didn’t work out ... , This can cause a sudden surge of people eager ...
(Date:7/12/2014)... Maxim Peptide, a website that features ... solely in scientific experiments, is currently celebrating its second ... Maxim Peptide, which was created by the founders of ... updated website that now features a special deals section. ... with fascinating articles about peptide research, including a new ...
(Date:7/11/2014)... July 11, 2014 The American Association ... 55 poison centers are commending Senator Bill Nelson (D-FL) ... Act of 2014 on July 10, 2014. Along with ... Products Safety Commission (CPSC) to enact rules requiring safer, ... , Senate co-sponsors of the bill include: ...
Breaking Medicine News(10 mins):Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 3
(Date:7/11/2014)... to study the proteins that let nerve cells send ... stumbled upon a biological tactic that may offer a ... a safe and environmentally responsible way. , Their ... one species and harmless for a closely related onesuggests ... without harming beneficial species like bees. A summary of ...
(Date:7/10/2014)... Fe, Albuquerque, and other major cities in New Mexico, ... treated municipal wastewater rather than precious potable water supplies. ... 40% of all golf courses receive treated effluent. Reusing ... , Additionally, golf courses and homeowners alike fertilize their ... fertilizer is nitrate. A New Mexico State University turfgrass ...
(Date:7/10/2014)... , June 27, 2014  Pomerantz LLP ... Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: PVCT) and ... in United States District Court, Middle District of ... on behalf of a class consisting of all ... Provectus securities between December 17, 2013 and May ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3'Tailored' water -- the latest in lawn care 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
Other TagsOther Tags